Extract from the Register of European Patents

EP About this file: EP1964839

EP1964839 - Quinazoline derivatives as kinase inhibitors [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  02.09.2011
Database last updated on 11.04.2026
Most recent event   Tooltip02.09.2011Refusal of applicationpublished on 05.10.2011  [2011/40]
Applicant(s)For all designated states
MILLENNIUM PHARMACEUTICALS, INC.
256 East Grand Avenue
South San Francisco, CA 94080 / US
For all designated states
KYOWA HAKKO KOGYO CO., LTD.
6-1, Ohtemachi 1-chome Chiyoda-ku
Tokyo 100-8185 / JP
[2008/36]
Inventor(s)01 / Pandey, Anjali
4506 Amiens Avenue
Fremont, CA 94555 / US
02 / Scarborough, Carroll (in Trust of Bob Scarborough)
22 Greenbier Court
Half Moon Bay, CA 94019 / US
03 / Matsuno, Kenji
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
04 / Ichimura, Michio
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
05 / Nomoto, Yuji
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
06 / Ide, Shinichi
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
07 / Tsukuda, Eiji
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
08 / Irie, Junko
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
09 / Oda, Shoji
1-6-1, Ohtemachie, 1-chome
Tokyo 100-8185 / JP
 [2008/50]
Former [2008/36]01 / Pandey, Anjali
256 E. Grand Avenue
South San Francisco, CA 94080 / US
02 / Scarborough, Robert, M.
256 E. Grand Avenue
South San Franciso, CA 94080 / US
03 / Matsuno, Kenji
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
04 / Ichimura, Michio
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
05 / Nomoto, Yuji
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
06 / Ide, Shinichi
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
07 / Tsukuda, Eiji
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
08 / Irie, Junko
1-6-1, Ohtemachi, 1-chome
Tokyo 100-8185 / JP
09 / Oda, Shoji
1-6-1, Ohtemachie, 1-chome
Tokyo 100-8185 / JP
Representative(s)Wombwell, Francis, et al
Forresters
15, Hamilton Square
Birkenhead
Merseyside CH41 6BR / GB
[N/P]
Former [2008/36]Wombwell, Francis, et al
Potts, Kerr & Co. 15, Hamilton Square Birkenhead
Merseyside CH41 6BR / GB
Application number, filing date08075237.117.08.2001
[2008/36]
Priority number, dateUS20000226122P18.08.2000         Original published format: US 226122 P
[2008/36]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1964839
Date:03.09.2008
Language:EN
[2008/36]
Type: A3 Search report 
No.:EP1964839
Date:05.11.2008
[2008/45]
Search report(s)(Supplementary) European search report - dispatched on:EP02.10.2008
ClassificationIPC:C07D403/12, C07D239/94, C07D401/12, A61P35/00, A61K31/517
[2008/36]
CPC:
C07D239/94 (EP,US); C07D401/14 (KR); A61K31/517 (EP,US);
A61P13/12 (EP); A61P35/00 (EP); A61P43/00 (EP);
A61P9/00 (EP); A61P9/02 (EP); A61P9/08 (EP);
A61P9/10 (EP); C07D401/12 (EP,US); C07D403/12 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2008/36]
TitleGerman:Quinazolinderivate als Kinasehemmer[2008/36]
English:Quinazoline derivatives as kinase inhibitors[2008/36]
French:Dérivés de quinazoline en tant qu'inhibiteurs de la kinase[2008/36]
Examination procedure02.04.2009Examination requested  [2009/21]
11.05.2009Despatch of a communication from the examining division (Time limit: M06)
23.11.2009Reply to a communication from the examining division
04.05.2011Date of oral proceedings
16.05.2011Minutes of oral proceedings despatched
18.05.2011Despatch of communication that the application is refused, reason: substantive examination [2011/40]
28.05.2011Application refused, date of legal effect [2011/40]
Parent application(s)   TooltipEP01964612.4  / EP1315715
Divisional application(s)EP10182322.7  / EP2277877
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20010964612) is  08.12.2003
Fees paidRenewal fee
31.03.2008Renewal fee patent year 03
31.03.2008Renewal fee patent year 04
31.03.2008Renewal fee patent year 05
31.03.2008Renewal fee patent year 06
31.03.2008Renewal fee patent year 07
31.03.2008Renewal fee patent year 08
25.08.2009Renewal fee patent year 09
25.08.2010Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XD] EP0882717  (KYOWA HAKKO KOGYO KK et al.)
 [PA] EP1067123  (KYOWA HAKKO KOGYO KK et al.)
 [PA] WO9951582  (KYOWA HAKKO KOGYO KK et al.)
by applicantZA6706512
 JPH05208911
 WO9609294
 WO9220642
 JPH0687834
 WO9814431
   CELL, vol. 46, 1986, pages 155 - 169
   SCIENCE, vol. 253, 1991, pages 1129 - 1132
   NIPPON RINSHO, JAPANESE J. OF CLINICAL MEDICINE, vol. 50, 1992, pages 3038 - 3045
   NEPHROL DIAL TRANSPLANT, vol. 10, 1995, pages 787 - 795
   KIDNEY INTERNATIONAL, vol. 43, no. 39, 1993, pages 86 - 89
   JOURNAL OF RHEUMATOLOGY, vol. 21, 1994, pages 1507 - 1511
   SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 27, 1988, pages 285 - 294
   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 53, 1996, pages 87 - 97
   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, 1996, pages 417 - 425
   INDIAN JOURNAL OF CHEMISTRY, vol. 26B, 1987, pages 550 - 555
   CANCER RESEARCH, vol. 54, 1994, pages 6106
   KANAZAWA, ABSTRACTS OF THE 16TH ANNUAL MEETING OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 2, 1996, pages 275
   T. W. GREENE: "Protective Groups in Organic Synthesis", 1981, JOHN WILEY & SONS INC.
   R. C. LAROCK, COMPREHENSIVE ORGANIC TRANSFORMATIONS, 1989
   J. IMMUNOL. METHODS, vol. 142, 1991, pages 257 - 265
   IKEDA ET AL., ANNUAL REPORT OF TOLCYO METROPOLITAN RESEARCH LABORATORIES P. H., vol. 36, 1985, pages 277
   MORIYAMA ET AL., HINYO KIYO, vol. 40, 1994, pages 565
   KLOMPMALCERS ET AL., ANALYTICAL BIOCHEMISTRY, vol. 153, 1986, pages 80
   MIESEL ET AL., INFLAMMATION, vol. 17, 1993, pages 595
   TRACEY ET AL., JOURNAL OF PHARMACOLOGY & EXPERIMENTAL THERAPEUTICS, vol. 272, 1995, pages 1011
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.